Skip to main content
. 2016 Sep 20;7(43):70613–70622. doi: 10.18632/oncotarget.12138

Figure 3. shRNA knockdown of Ppm1e activates AMPK and protects osteoblastic cells from Dex.

Figure 3

OB-6 cells were infected with lentiviral Ppm1e shRNA (“−1 or −2”) or non-sense control shRNA (“scr shRNA”), and stable cells were established. miR-135b and Ppm1e mRNA levels were tested (A, qRT-PCR assay), Ppm1e protein expression and AMPK activation (p-AMPK/p-ACC) were also tested (B, Western blot assay). Above cells were treated with or without Dex (1 μM) for 24 hours, cell viability (C, MTT assay) and apoptosis (D, Histone DNA ELISA assay) were shown. Ppm1e shRNA (“-1”)-expressing OB-6 cells were transfected with miR-135b expressing construct, expressions of miR-135b E. and Ppm1e mRNA F. were tested by qRT-PCR assay, these cells were also treated with or without Dex (1 μM) for 24 hours, cell viability G. and apoptosis H. were shown. “Ctrl” stands for untreated control group. Experiments in this figure were repeated four times, and similar results were obtained. *p<0.05 vs. “scr shRNA” cells (A, C-H).